Minghui Pharmaceutical
ID: 17842575Minghui Pharmaceutical is a Shanghai-based, late-stage biopharmaceutical company pioneering next-generation immuno-oncology therapies, including PD-1/VEGF bispecifics, IGF-1R inhibitors, and its lead B7-H3 ADC (MHB088C). In mid-2025, it secured USD 186 million licensing plus milestone and royalty payments from Qilu Pharma for Greater China rights.
1
Funding Rounds
$131.0m
Money raised
Recent Funding Rounds
Overview
- Website:
- Business model: B2B
Unlock Complete Company Intelligence
Access comprehensive data and insights available only to Seedtable members
Financial Details
- • Complete funding history and valuations
- • Revenue estimates and financial metrics
- • Investment round details and terms
People & Contacts
- • Complete leadership team profiles
- • Contact information and email addresses
- • Board members and advisors
Market Intelligence
- • Competitive landscape analysis
- • Market position and growth metrics
- • Industry benchmarking data
Premium Tools
- • Export data and generate reports
- • Save companies to custom watchlists
- • API access for data integration
Join 10,000+ Professionals
Trusted by investors, founders, and analysts worldwide
Access detailed insights on 71,000+ companies worldwide
Funding series
Funding Series Analysis
The company Minghui Pharmaceutical has raised a total of $131m in funding over 1 rounds.
Key Insights:
- Minghui Pharmaceutical August 2025 IPO Funding Round: $131m